Advanced searches left 3/3

Cefepime - Crossref

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

Cefepime-Induced Nonconvulsive Status Epilepticus in a Pediatric Patient with Normal Renal Function

In the context of impaired renal function in adults, the most apparent are neurotoxic effects of cefepime, but in those with normal renal excretion function or in the pediatric population, there are no such issues. After beginning cefepime therapy, any patient with or without impaired renal function that causes significant changes in mental stability, as well as reduced alerts, should be considered in any patient with acute changes in mental stability and/or reduced consciousness.

Source link: https://doi.org/10.1177/2329048x221119575


Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia

OBJECT BACTERIAL – Foodborne Vibrio vulnificus infections are linked to higher rates of sepsis and mortality than wound infections; however, antibiotic efficacy studies have not been conducted in foodborne infection models. In order to simulate foodborne infections, the efficacies of ceftriaxone, cefepime, oxycycline, ciprofloxacin, and combination therapy were tested in mice of V. vulnificus intestinal disease in mice. We conclude that combined therapy was the most effective therapy for foodborne V. vulnificus septicemia. For coverage of infectious Gram-negative organisms and V. vulnificus awaiting a microbiological diagnosis, a septic patient with a recent intake of raw seafood, cefepime in combination with doxycycline or ciprofloxacin should be started. Once a diagnosis of foodborne V. vulnificus septicemia is established, septicemia can be treated with ceftriaxone in combination with doxycycline or ciprofloxacin.

Source link: https://doi.org/10.1128/aac.01106-17


Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa mutants are characterized as having a variety of ceftazole/relebactam, cefepime/taniborbactam, cefepime/tam a mutants a bactam/tam/tam- and cefe/tam/tam/tam, bactam/tam, cefe/tam, cefe/tam/tam, and cefe/tam, and cefe/tam, and cefe/tam, and cefe/tam- and cefe/tam- and cefe/zidime To see how the different u03b2-lactamases in the clinical isolates affected the resistance to these proteins, we'll look at how the chroned blaPDC, blaOXA-2, and blaOXA-10 ancestral and mutant alleles from the clinical isolates was cloned in pUCp24 or single oprD PAO1 knockout mutants were cloned in pUCp24. Except two clinical isolates that carried the VIM-20 carbapenemase, imipenem/relebactam was extremely active against all isolates, except two clinical isolates that carried the VIM-20 carbapenemase. The isolates in Cefepime/zidebactam and cefepime/taniborbactam had activity against the majority of the isolates, but resistance was observed in some strains with PBP3 amino acid substitutions or that overexpressed mexAB-oprM or mexy efflux pumps. These agents may have potential therapeutic options for ceftolobactam- and ceftazidime/avibactam-resistant P. aeruginosa infections, according to these agents.

Source link: https://doi.org/10.1093/jac/dkac241


Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Objects: Objectives: To determine the in vitro activity of cefepime/zidebactam and comparators against 24 220 Gram-negative bacteria, we need to determine the in vitro activity of cefepime/zidebactam and comparators against 24 220 Gram-negative bacteria. Cefepime/zidebactam was tested at a 1:1 ratio. Cefepime/zidebactam was particularly effective against Enterobacteria and remained potent against carbapenem-resistant Enterobacterales isolates. CRE rates in the U. S. varied from 1. 1% to 1. 9% in W-EU, 3. 6 percent in APAC, and 14. 6% in E-EU. blaKPC, blaOXA-48-like, and blaNDM were the most common carbapene genes detected overall, according to a blaKPC, blaOXA-48-like, and blaNDM. CRE's resistance to ceftazidime/avibactam was at an all-time peak in APAC, E-EU, and LATAM. Cidemime/zidebactam was the lowest in E-EU isolates found against Pseudomonas aeruginosa, with ceftazidime/avibactam and ceftolozane/tazobactam reduced by 92% of isolates at u22648 mg/L and susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam Cefepime/zidebactam was a good match against Stenotrophomonas maltophilia and Burkholderia cepacia. Conclusions Cefepime/zidebactam showed potent in vitro activity against a large worldwide group of Gram-negative bacteria isolates.

Source link: https://doi.org/10.1093/jac/dkac233


Assessing the association between cefepime percentage free trough level and neurotoxicity

It has been speculated that cefepime neurotoxicity is connected to elevated doses of the drug. However, studies looking for a correlation between serum drug level and the incidence of neurotoxicity have yet to establish a single threshold. Method: To obtain percentage free trough values, infectious diseases pharmacists who received cefepime from January 2019 to November 2021 were tested by infectious diseases pharmacists who conducted institutional standard dosing regimens for at least 72 hours. Cefepime percentage free trough levels were considered therapeutic if they were over the prescribed minimum inhibitory concentration of the treated organism and were below 40 u03bcg/mL. Patients with creatinine clearance 60 mL/min were more likely to have neurotoxicity-related symptoms than those without. Patients with reduced creatinine clearance were considerably more likely to have neurologic findings consistent with cefepime-induced neurotoxicity.

Source link: https://doi.org/10.1017/ash.2022.100

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions